CD19: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD19. The page also collects GeneMedi's different modalities and formats products for CD19 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD19 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Target IDGM-T56365
Target NameCD19
Gene ID930,12478,365367,705211,607898,100125860,517359,100147468
Gene Symbol and SynonymsB4,CD19,CVID3
Uniprot AccessionP15391
Uniprot Entry NameCD19_HUMAN
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, Immuno-oncology Target, INN Index
DiseaseCancer
Gene EnsemblENSG00000177455
Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)


Pre-made CD19-specific INN-index biosimilar (antibody&conjugates)

Anti-CD19 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatDetail
GMP-Bios-ab-383Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyObexelimabCD19Whole mAbDetail
GMP-Bios-ab-116Pre-Made Coltuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyColtuximabCD19Whole mAb ADCDetail
GMP-Bios-ab-320Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyLoncastuximabCD19Whole mAb ADCDetail
GMP-Bios-INN-1008Pre-Made Taplitumomab Paptox biosimilar, Fusion Protein, Taplitumomab-Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody staplitumomab paptoxCD19Fusion ProteinDetail
GMP-Bios-ab-543Pre-Made Tafasitamab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyTafasitamabCD19Whole mAbDetail
GMP-Bios-INN-745azercabtagene zapreleucelCD19Engineering T cellDetail
GMP-Bios-ab-074Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibodyBlinatumomabCD19;CD3EBispecific T-Cell EngagerDetail
GMP-Bios-ab-273Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyInebilizumabCD19Whole mAbDetail
GMP-Bios-ab-664Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3EnsomafuspCD19Fusion ProteinDetail
GMP-Bios-INN-786Pre-Made Coltuximab Ravtansine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugatecoltuximab ravtansineCD19Whole mAb ADCDetail
GMP-Bios-INN-896Pre-Made Loncastuximab Tesirine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugateloncastuximab tesirineCD19Whole mAb ADCDetail
GMP-Bios-ab-139Pre-Made Denintuzumab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyDenintuzumabCD19Whole mAb ADCDetail
GMP-Bios-INN-836Pre-Made Ensomafusp Alfa? Alfaiosimilar, Bispecific, Anti-Cd19; Tnfrsf9 Antibody: Anti-B4/CVID3;ILA/4-1BB/CDw137 therapeutic antibodyensomafusp alfaCD19;TNFRSF9BispecificDetail
GMP-Bios-INN-800Pre-Made Denintuzumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugatedenintuzumab mafodotinCD19Whole mAb ADCDetail
GMP-Bios-ab-161Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibodyDuvortuxizumabCD19;CD3EBispecific scFv with CrossoverDetail

Click to check more INN-indexed antibody & protein biosimilar



Pre-made anti-CD19 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD19 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD19 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-CD19 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional Antibody, Therapeutics Target antibodyDetail



Multi-species CD19/ B4/ CVID3 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CD19 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
CD19 VLP (virus-like particle)Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellProducts Developing



Pre-made CD19 viral vector in GM Promise-ORFTM

Cat No.Products nameNM IDSpeciesTypeDetail
pGMLP002732human CD19 Lentivirus plasmidNM_001770HumanLentivirus plasmidDetail
vGMLP002732human CD19 Lentivirus particleNM_001770HumanLentivirus particleDetail
pGMLPm001604mouse Cd19 Lentivirus plasmidNM_001357091MouseLentivirus plasmidDetail
pGMLPm005418mouse Cd19 Lentivirus plasmidXM_006507282.3MouseLentivirus plasmidDetail
vGMLPm001604mouse Cd19 Lentivirus particleNM_001357091MouseLentivirus particleDetail
vGMLPm005418mouse Cd19 Lentivirus particleXM_006507282.3MouseLentivirus particleDetail

About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI

If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<